Apogee Therapeutics (APGE) CMO sells shares under 10b5-1 trading plan

Rhea-AI Filing Summary

Apogee Therapeutics Chief Medical Officer Carl Dambkowski reported option exercises and share sales. On March 4, 2026, he exercised stock options for 4,125 shares and acquired 4,125 shares of common stock at $22.86 per share. He then sold a total of 5,500 common shares in three open-market transactions at weighted average prices of $70.33, $71.98 and $73.26 per share, executed under a Rule 10b5-1 trading plan adopted on September 22, 2025. Following these trades, he held 209,773 shares of Apogee Therapeutics common stock directly.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Dambkowski Carl

(Last) (First) (Middle)

C/O APOGEE THERAPEUTICS, INC.

221 CRESCENT ST., BLDG. 17, STE. 102B

(Street)

WALTHAM MA 02453

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Apogee Therapeutics, Inc. [ APGE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Medical Officer

3. Date of Earliest Transaction (Month/Day/Year)
03/04/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/04/2026		M		4,125	A	$22.86	215,273	D
Common Stock	03/04/2026		S(1)		3,225	D	$70.33(2)	212,048	D
Common Stock	03/04/2026		S(1)		2,075	D	$71.98(3)	209,973	D
Common Stock	03/04/2026		S(1)		200	D	$73.26(4)	209,773	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$22.86	03/04/2026		M			4,125	(5)	12/18/2033	Common Stock	4,125	$0.00	131,290	D

Explanation of Responses:

1. This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 22, 2025.

2. The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $70.30 to $70.82, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission ("SEC"), upon request, full information regarding the number of shares sold at each separate price within the range.

3. The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $71.51 to $72.45, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.

4. The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $73.20 to $73.31, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.

5. This option represents the right to purchase 175,345 shares of the Issuer's common stock, which will vest in forty-eight equal monthly installments through December 18, 2027, subject to the Reporting Person's continued service to the Issuer.

	/s/ Matthew Batters, as attorney-in-fact for Carl Dambkowski	03/06/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did Apogee Therapeutics (APGE) CMO report on March 4, 2026?

Apogee Therapeutics Chief Medical Officer Carl Dambkowski exercised options for 4,125 shares and sold 5,500 common shares. The sales occurred in three open-market transactions at weighted average prices above $70 per share, all under a pre-arranged Rule 10b5-1 trading plan.

How many Apogee Therapeutics (APGE) shares did the CMO sell and at what prices?

Carl Dambkowski sold 5,500 Apogee Therapeutics common shares in three transactions. The weighted average sale prices were $70.33, $71.98 and $73.26 per share, each representing multiple trades within stated price ranges disclosed in the filing’s footnotes.

How many Apogee Therapeutics (APGE) shares does the CMO hold after these transactions?

After the reported trades, Carl Dambkowski directly holds 209,773 shares of Apogee Therapeutics common stock. This figure reflects his position following the option exercise for 4,125 shares and subsequent open-market sales totaling 5,500 shares on March 4, 2026.

Were Apogee Therapeutics (APGE) CMO’s share sales pre-planned under Rule 10b5-1?

Yes. The filing states the sales were executed pursuant to a Rule 10b5-1 trading plan adopted on September 22, 2025. Such plans allow insiders to schedule trades in advance, providing a structured framework for selling shares over time.

What stock option activity did the Apogee Therapeutics (APGE) CMO report?

Carl Dambkowski exercised a stock option for 4,125 shares on March 4, 2026. A related footnote explains the option covers 175,345 shares in total and vests in forty-eight equal monthly installments through December 18, 2027, contingent on his continued service.

What is the vesting schedule of the Apogee Therapeutics (APGE) option mentioned in the filing?

The option referenced in the filing represents the right to purchase 175,345 Apogee Therapeutics common shares. It vests in forty-eight equal monthly installments through December 18, 2027, and remains subject to Carl Dambkowski’s continued service with the company over that period.